Company secures solo booth for third consecutive year at world's top ADC conference, highlighting integrated CRO, CDO and CMO services from a single Songdo campus; bispecific antibody and organoid technologies on display

Mark Studer, head of Samsung Biologics' ADC and mRNA operations team, presents the company's efforts and achievements in securing commercial ADC production capabilities at World ADC San Diego 2026 in San Diego, California, on Wednesday (local time). [Samsung Biologics]
Mark Studer, head of Samsung Biologics' ADC and mRNA operations team, presents the company's efforts and achievements in securing commercial ADC production capabilities at World ADC San Diego 2026 in San Diego, California, on Wednesday (local time). [Samsung Biologics]

Samsung Biologics showcased its end-to-end contract development and manufacturing capabilities at the world's largest antibody-drug conjugate conference.

The company announced Monday that it participated in World ADC San Diego 2026, held over four days from Oct. 12 to 15 (local time) in San Diego, California. The event draws more than 400 companies and roughly 1,300 specialists, making it the most prestigious gathering in the ADC field.

Samsung Biologics set up a solo booth for the third consecutive year, promoting its integrated service capabilities spanning contract research, development and manufacturing.

The company particularly emphasized its ability to handle every step of the process — from cell line development through conjugation, analysis and production — at a single campus in Songdo, Incheon, leveraging its existing antibody biopharmaceutical production capabilities. Samsung Biologics plans to complete its full-cycle service offering by building a dedicated drug product finishing line by 2027, following the launch of a dedicated ADC production facility in March 2025.

Technical sessions were also held at the conference. Mark Studer, head of operations, presented on "From Drug Asset to Commercial Production: Key Success Factors in Scaling ADC GMP Manufacturing," sharing the company's conjugation service expansion plans and commercial production achievements.

Poster presentations covered the development of bispecific antibody ADCs using the company's proprietary bispecific antibody platform S-DUAL, as well as drug evaluation technology employing Samsung Organoid, a patient-derived organoid screening platform.

"Through World ADC, we highlighted our CDMO capabilities to meet the increasingly diverse needs of customers — from antibody drugs to ADCs, bispecific antibodies and organoids," said Lee Sang-myung, executive vice president of CDO development at Samsung Biologics. "We will continue to expand our capabilities in new modalities such as peptides to strengthen our end-to-end competitiveness."

The company's participation reflects a broader strategy to extend its top-ranked antibody biopharmaceutical production capabilities into the ADC space, positioning its Songdo, Incheon campus as a one-stop destination for everything from development to finished-product manufacturing — and using that integrated offering to win contracts from global pharmaceutical majors.


silverpaper@heraldcorp.com